METFORMIN HYDROCHLORIDE tablet, film coated

Valsts: Amerikas Savienotās Valstis

Valoda: angļu

Klimata pārmaiņas: NLM (National Library of Medicine)

Aktīvā sastāvdaļa:

METFORMIN HYDROCHLORIDE (UNII: 786Z46389E) (METFORMIN - UNII:9100L32L2N)

Pieejams no:

Major Pharmaceuticals

SNN (starptautisko nepatentēto nosaukumu):

METFORMIN HYDROCHLORIDE

Kompozīcija:

METFORMIN HYDROCHLORIDE 500 mg

Ievadīšanas:

ORAL

Receptes veids:

PRESCRIPTION DRUG

Ārstēšanas norādes:

Metformin hydrochloride tablets USP is indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 2 diabetes mellitus. Metformin hydrochloride is contraindicated in patients with: Metformin hydrochloride should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because use of such products may result in acute alteration of renal function. (See also PRECAUTIONS. )

Produktu pārskats:

Metformin hydrochloride tablets USP: Metformin hydrochloride tablets 500 mg are white to off-white, round shape, biconvex coated tablets debossed with "227" on one side and plain on the other side. Bottles of 100                          : NDC 67877-217-01 Bottles of 500                          : NDC 67877-217-05 Bottles of 1000                        : NDC 67877-217-10 Metformin hydrochloride tablets 850 mg are white to off-white, round shape, biconvex coated tablets debossed with "228" on one side and plain on the other side. Bottles of 100                          : NDC 67877-218-01 Bottles of 500                          : NDC 67877-218-05 Bottles of 1000                        : NDC 67877-218-10 Metformin hydrochloride tablets 1000 mg are white to off white, oval, capsule shaped, biconvex, coated tablets debossed with “229/229” on one side and a bisect line on both sides. Bottles of 100                          : NDC 67877-221-01 Bottles of 500                          : NDC 67877-221-05 Bottles of 1000                        : NDC 67877-221-10 Store at 20°–25° C (68°–77° F); excursions permitted to 15°–30° C (59°–86° F). [See USP Controlled Room Temperature.]  Dispense in light-resistant containers.   Manufactured by: Alkem Laboratories Limited ALKEM HOUSE, Lower Parel, Mumbai – 400 013, INDIA May, 2012 Distributed by: Ascend Laboratories, LLC. Montvale, NJ 07645   Distributed by: MAJOR® PHARMACEUTICALS Livonia, MI 48150 REFER TO PACKAGE LABEL FOR DISTRIBUTOR"S NDC NUMBER PT1260-04

Autorizācija statuss:

Abbreviated New Drug Application

Produkta apraksts

METFORMIN HYDROCHLORIDE- METFORMIN HYDROCHLORIDE TABLET, FILM COATED
MAJOR PHARMACEUTICALS
----------
METFORMIN HYDROCHLORIDE TABLETS USP
BOXED WARNING
LACTIC ACIDOSIS:
LACTIC ACIDOSIS IS A RARE, BUT SERIOUS, METABOLIC COMPLICATION THAT
CAN OCCUR DUE TO
METFORMIN ACCUMULATION DURING TREATMENT WITH METFORMIN; WHEN IT
OCCURS, IT IS FATAL IN
APPROXIMATELY 50% OF CASES. LACTIC ACIDOSIS MAY ALSO OCCUR IN
ASSOCIATION WITH A NUMBER
OF PATHOPHYSIOLOGIC CONDITIONS, INCLUDING DIABETES MELLITUS, AND
WHENEVER THERE IS
SIGNIFICANT TISSUE HYPOPERFUSION AND HYPOXEMIA. LACTIC ACIDOSIS IS
CHARACTERIZED BY ELEVATED
BLOOD LACTATE LEVELS (>5 MMOL/ L), DECREASED BLOOD PH, ELECTROLYTE
DISTURBANCES WITH AN
INCREASED ANION GAP, AND AN INCREASED LACTATE/PYRUVATE RATIO. WHEN
METFORMIN IS IMPLICATED
AS THE CAUSE OF LACTIC ACIDOSIS, METFORMIN PLASMA LEVELS >5 ΜG/ML ARE
GENERALLY FOUND.
THE REPORTED INCIDENCE OF LACTIC ACIDOSIS IN PATIENTS RECEIVING
METFORMIN HYDROCHLORIDE IS
VERY LOW (APPROXIMATELY 0.03 CASES/1000 PATIENT-YEARS, WITH
APPROXIMATELY 0.015 FATAL
CASES/1000 PATIENT-YEARS). IN MORE THAN 20,000 PATIENT-YEARS EXPOSURE
TO METFORMIN IN
CLINICAL TRIALS, THERE WERE NO REPORTS OF LACTIC ACIDOSIS. REPORTED
CASES HAVE OCCURRED
PRIMARILY IN DIABETIC PATIENTS WITH SIGNIFICANT RENAL INSUFFICIENCY,
INCLUDING BOTH INTRINSIC
RENAL DISEASE AND RENAL HYPOPERFUSION, OFTEN IN THE SETTING OF
MULTIPLE CONCOMITANT
MEDICAL/SURGICAL PROBLEMS AND MULTIPLE CONCOMITANT MEDICATIONS.
PATIENTS WITH CONGESTIVE
HEART FAILURE REQUIRING PHARMACOLOGIC MANAGEMENT, IN PARTICULAR THOSE
WITH UNSTABLE OR
ACUTE CONGESTIVE HEART FAILURE WHO ARE AT RISK OF HYPOPERFUSION AND
HYPOXEMIA, ARE AT
INCREASED RISK OF LACTIC ACIDOSIS. THE RISK OF LACTIC ACIDOSIS
INCREASES WITH THE DEGREE OF
RENAL DYSFUNCTION AND THE PATIENT'S AGE. THE RISK OF LACTIC ACIDOSIS
MAY, THEREFORE, BE
SIGNIFICANTLY DECREASED BY REGULAR MONITORING OF RENAL FUNCTION IN
PATIENTS TAKING METFORMIN
AND BY USE OF THE MINIMUM EFFECTIVE DOSE OF METFORMIN. IN PARTICULAR,
TREATMENT OF THE
ELDERLY SHOULD BE ACCOMPA